![spectrumheader4r](http://osteoremedies.wpengine.com/wp-content/uploads/2019/04/spectrumheader4r-1.jpg)
![spectrumbeauty](http://osteoremedies.wpengine.com/wp-content/uploads/2019/03/spectrumbeauty-1.jpg)
![subheaderpower](http://osteoremedies.wpengine.com/wp-content/uploads/2019/03/subheaderpower.png)
![left-bullets](http://osteoremedies.wpengine.com/wp-content/uploads/2019/03/left-bullets-1.png)
![graph1](http://osteoremedies.wpengine.com/wp-content/uploads/2019/03/graph1.png)
![subheader2anti](http://osteoremedies.wpengine.com/wp-content/uploads/2019/03/subheader2anti.png)
![spectrumsidebarr](http://osteoremedies.wpengine.com/wp-content/uploads/2019/04/spectrumsidebarr.jpg)
![Chart-1r](http://osteoremedies.wpengine.com/wp-content/uploads/2019/04/Chart-1r.jpg)
![Chart-2r](http://osteoremedies.wpengine.com/wp-content/uploads/2019/04/Chart-2r.jpg)
![Chart-3r](http://osteoremedies.wpengine.com/wp-content/uploads/2019/04/Chart-3r.jpg)
SPECTRUM® GV Bone Cement was tested in Lab A, Palacos® R+G in Lab B, and Palacos® 1g Vanc and Palacos® 2g Vanc were tested in Lab C
![longgraphr](http://osteoremedies.wpengine.com/wp-content/uploads/2019/04/longgraphr-1.jpg)
1 For complete data and associated risks reference the REMEDY SPECTRUM® GV Hip IFU. In a review of 22 patients, clinical effectiveness was defined as the absence of 2 or more positive cultures at the time of reimplanation. Patients should be monitored for ototoxicity and nephrotoxicity while under-going treatment for PJI.
2 Bishop, A., et al., 2018. Data in Brief. 20. 14-19.
3 Carann, R. et al., 2013. World Journal of Orthopaedics. 9327(36).